Anti-Human CD223 Recombinant Antibody(Relatlimab)
-
产品编号
YR1487
-
别名
科研级 Relatlimab ( 瑞拉利单抗 ), Anti-CD223 Recombinant Antibody, Research Grade Relatlimab
-
规格
- 1mg
- 5mg
产品介绍
| Alias | 科研级 Relatlimab ( 瑞拉利单抗 ), Anti-CD223 Recombinant Antibody, Research Grade Relatlimab |
| Catalog Number | YR1487 |
| Molecular Name | Relatlimab |
| Size | 1mg, 5mg |
| Clonity | Monoclonal |
| Purity | >95% as determined by SDS-PAGE |
| Concentration | 1mg/ml |
| Antibody Isotype | IgG4 Kappa |
| Formulation | PBS, pH7.5 |
| Background | Relatlimab (INN, development code BMS-986016) is a monoclonal antibody designed for the treatment of melanoma. This drug is being developed by Bristol-Myers Squibb. As of 2018, relatlimab is undergoing Phase II/III trials. |
| CAS Number | 1673516-98-7 |
| Storage Condition | It is recommended to aliquote and store at -20°C for long term storage. Avoid repeated freezing and thawing cycles. |
| Remarks | This product is for research use only. |
| Shipping Condition | Shipped on ice packs. |
| Target | CD223[Homo sapiens] |
-
400-621-6806 -
614353794 -
周一至周五 9:00-18:00 -
-
0
-
